Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004Rritual Superfoods Ready to Launch Amazon Store in USAAtai Life Sciences Is Setting The Stage For The Largest IPO The Psychedelics Sector Has Seen To DateEntheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available fMajor U.S. States Are Taking A Serious Look At Decriminalizing Psychedelic Compounds For The Treatment Of Mental IllnessMAPS Canada Is Leading The Global Charge To Commercialize Psychedelic TherapiesBetterLife Pharma Appoints Henri Sant-Cassia of The Conscious Fund to its Board of DirectorsMindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic MedicineTryp Therapeutics Partners with Alcami for Proprietary FormulationsHAVN Life Secures Production & Supply Agreement to Expand Retail Product OfferingsCybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery MechanismsNuminus Wellness Is One Of The Shining Stars Of The Psychedelic SectorPsychedelic Stocks Are Starting To Get Some Serious Traction In The Mainstream MediaMAPS Canada Is Leading The Way For Psychedelic Use Cases In Modern MedicineRritual Superfoods Initiates Canadian Retail Growth Strategy Signing with Ultimate Sales CanadaNuminus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for SevTryp Therapeutics Partners with Clinlogix for Clinical Trial SupportTryp Therapeutics Partners with Fluence for Psychotherapy DesignTryp Therapeutics Announces Q2 2021 Financial ResultsRritual Announces CROSSMARK Partnership to Optimize Retail Growth
Back

Will The ATAI Life Sciences IPO Bring Investor Interest Back To the Psychedelics Sector?

Apr 23, 2021 • 8:06 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Although the psychedelic sector has come off its 2021 highs, we believe the sector is barely in the first inning of a major growth cycle. 

Several psychedelic therapy companies are in advanced US Food and Drug Administration (FDA) clinical trials and we expect positive data from these studies to serve as a catalyst for the entire industry.

ATAI Life Sciences, a biopharmaceutical company that is focused on commercializing psychedelic therapies to treat mental health disorders, is considered to be a leader in the psychedelic therapy market and recent announced plans to raise $100 million in an initial public offering (IPO).

Billionaire investor Peter Thiel is a high-profile investor in ATAI and we are favorable on his involvement. Thiel is a large investor in other psychedelic therapy companies and we are favorable on this due to his track record of success.  

The IPO filing shows that ATAI has raised $362.3 million from private investors so far. With this amount of capital, we believe the company is well positioned to execute on its clinical trials and are favorable on the strength of its balance sheet. 

As it relates to ATAI’s IPO, the underwriters include Credit Suisse, Citigroup, Cowen, and Berenberg. Although a date for the IPO has not been announced, the psychedelic therapy company plans to list on the Nasdaq under the symbol, ATAI.

When compared to other psychedelic therapy companies, we consider ATAI to be a differentiated opportunity. The company describes itself as a drug development platform that was formed to acquire, incubate and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction and other mental health conditions.

ATAI has partnered with 14 companies that are focused on drug development and other technologies. The company receives a majority ownership stake from the drugs and technologies that it partners with and we are favorable on this structure. In return, ATAI helps with raising capital, working with the regulators, and conducting clinical trials.

We are excited about ATAI’s planned IPO and believe that our readers need to be aware of the opportunity. If you are interested in learning more about ATAI Life Sciences, please send an email to support@technical420.com with the subject “ATAI Life Sciences” to be added to our distribution list. 

For the fastest access to data on ATAI Life Sciences, you can sign up for our free newsletter!

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link